Orforglipron

Human clinical Weight Loss & Metabolism 2 sources

Orforglipron is a novel, orally administered, non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist. Research shows it effectively stimulates insulin secretion, delays gastric emptying, and promotes significant weight loss and glycemic control without the strict fasting protocols required by other oral GLP-1s.

01Dosing reference

Amount

12 to 45 mg per day (in clinical trials)

Frequency

Once daily

Cycle

Continuous daily use

Reference figures, not a recommendationThese values reflect amounts described in the literature and vendor documentation this database indexes. Use the reconstitution calculator to convert them into syringe units.

02Mechanism of action

GLP-1 Receptor Activation

Binds to and activates the GLP-1 receptor as a non-peptide small molecule.

Incretin Effect Enhancement

Stimulates glucose-dependent insulin release, suppresses glucagon secretion, and slows gastric emptying.

Metabolic Regulation

Leads to improved blood glucose levels and reduced appetite, facilitating significant weight loss.

03Human evidence

Significant weight reduction of up to 14.7% at 36 weeks compared to placebo.

Phase 2 clinical trial in adults with obesity or overweight with at least one weight-related coexisting condition.

Significant HbA1c reduction and weight loss compared to placebo and dulaglutide.

Phase 2 clinical trial in patients with type 2 diabetes over 26 weeks.

04Preclinical evidence

Potent partial agonism at the GLP-1 receptor, potentially leading to less receptor desensitization.

In vitro cellular assays evaluating receptor binding and activation kinetics.

Robust efficacy in reducing food intake and body weight.

Animal models of obesity and diabetes used during preclinical development.

05What is known vs. unknown

Reasonably established

It is a non-peptide small molecule, allowing for standard oral administration.
Does not require strict fasting conditions for absorption, unlike oral semaglutide.
Shows comparable efficacy to injectable GLP-1 receptor agonists in early trials.
Currently in Phase 3 clinical trials for obesity and type 2 diabetes.

Unknowns & limits

Long-term cardiovascular safety and outcomes are still being evaluated in ongoing Phase 3 trials.
Real-world tolerability and adherence compared to once-weekly injectables remain to be fully established.

06Safety & regulatory context

Regulatory statusOrforglipron is currently an investigational drug and is not yet FDA-approved. In clinical trials, the most common side effects are gastrointestinal, including nausea, vomiting, diarrhea, and constipation, which are typical for the GLP-1 receptor agonist class. These effects are generally mild to moderate and occur mostly during the dose-escalation phase.

07Compared with Oral Semaglutide (Rybelsus)

Orforglipron vs. Oral Semaglutide (Rybelsus)

Key difference

Orforglipron is a non-peptide small molecule that does not require strict fasting before and after dosing, whereas oral semaglutide is a peptide that requires strict fasting for absorption.

When researchers discuss each

Oral semaglutide is discussed as the first approved oral GLP-1, while orforglipron is discussed as the next-generation oral option with easier administration rules.

08Glossary

GLP-1 Receptor Agonist

A class of drugs that mimic the incretin hormone GLP-1 to increase insulin and decrease glucagon.

Non-peptide small molecule

A chemical compound with a low molecular weight that is not made of amino acids, often allowing for easier oral absorption.

HbA1c

A blood test that measures average blood sugar levels over the past 2-3 months.

09Knowledge check

Q1What is the primary advantage of orforglipron's non-peptide structure compared to oral semaglutide?

Q2What are the most common side effects observed in orforglipron clinical trials?

Q3Which statement best reflects a documented limitation of the current clinical evidence for orforglipron?

Q4In published discussions comparing orforglipron with oral semaglutide, what contextual description do researchers use?

Q5Which statement about orforglipron's regulatory status and commonly observed adverse events is supported by the dossier?

10Sources

More in Weight Loss & Metabolism

See all

AOD-9604

Weight Loss & Metabolism

Human clinical

AOD-9604 is a modified fragment of human growth hormone (HGH) that includes amino acids 177-191. Research indicates it mimics the fat-burning effects of HGH by stimulating lipolysis and inhibiting lipogenesis, without the adverse effects on blood sugar or tissue growth typically associated with full-length HGH.

250-500 mcg/day

MOTS-c

Weight Loss & Metabolism

Early human

MOTS-c is a naturally occurring mitochondrial-derived peptide that plays a key role in regulating metabolic homeostasis and energy production. Research indicates it acts as an 'exercise mimetic' by activating AMPK, improving insulin sensitivity, and enhancing physical performance in animal models.

5-10 mg

GLP3-RT (Retatrutide)

Weight Loss & Metabolism

Human clinical

Retatrutide is an investigational triple hormone receptor agonist that targets GLP-1, GIP, and glucagon receptors. Clinical trials have shown unprecedented weight loss efficacy, surpassing dual agonists, by combining appetite suppression with increased energy expenditure.

N/A - Investigational Drug

Research and educational use onlyNothing on this site is medical advice, a prescription, or a recommendation for human use. Compounds documented here are research chemicals. Consult a qualified clinician before making any health decision.